Emerging Drug Developer: Synosia Therapeutics

Synosia Therapeutics

Back in 2005, Synosia Therapeutics was little more than a gleam in a venture capitalist's eye.

Bradley Bolzon, an experienced biotech player and an accomplished dealmaker with Roche, had gone on to become a partner at Versant Ventures. Several years ago he reached out to an old colleague from Roche days, Ian Massey, a 30-year biotech veteran and the senior vice president of research and preclinical development for Roche Palo Alto. An A1 round of $2.5 million to prime the pump was swiftly followed by an A2 round of $30 million. And today, Synosia has a portfolio of six clinical-stage therapeutics, four of which are either already in a mid-stage trial or ready to begin one. Article

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.